The Key Players in Global Human Insulin Market 2015-2019

Friday 14 August 2015, Amsterdam

The report recognizes the following companies as the key players in the Global Human Insulin Market: Lilly, Novo Nordisk and Sanofi

The other prominent vendors are: Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals,Macrogenics, Merck, Oramed Pharmaceuticals, Osiris Therapeutics, Thermalin Diabetes, Tolerion, Wockhardt and XOMA

Commenting on the report, an analyst said: “The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market.”

According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth.

Further, the report states that the global human insulin market is witnessing patent expiries for major brands.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Global Human Insulin Market 2015-2019

Global Human Insulin Market 2015-2019

Publish date : August 2015
Report code : ASDR-213623
Pages : 63 Media contact: S. Koopman - Marketing and Communications / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E :

 back to News